Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES-Reference-Cited by-同舟云学术

Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES

Published:2021-03-16 Issue:1 Volume:188 Page:77-89
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Im Young-Hyuck^ORCID,Karabulut Bulent,Lee Keun Seok,Park Byeong-Woo,Adhav Aditya,Cinkir Havva Yesil,Abdel-Razeq Hikmat,Chang Yuan-Ching,Aksoy Sercan,Im Seock-Ah,Jeong Joon,Chae Yeesoo,Bowles James,Slimane Khemaies,Xue Hongling,Kim Sung-Bae

Funder

Novartis Pharma AG, Basel, Switzerland

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-021-06173-z.pdf

Reference39 articles.

1. Breast cancer, early diagnosis and screening (2020) https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/. Accessed 6 Nov 2020

2. Yeo W, Ueno T, Lin CH, Liu Q, Lee KH, Leung R, Naito Y, Park YH, Im SA, Li H, Yap YS, Lu YS (2019) Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian breast cancer cooperative group 2019 consensus and position on ovarian suppression. Breast Cancer Res Treat 177:549–559. https://doi.org/10.1007/s10549-019-05318-5

3. El Saghir NS, Khalil MK, Eid T, El Kinge AR, Charafeddine M, Geara F, Seoud M, Shamseddine AI (2007) Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg 5:225–233. https://doi.org/10.1016/j.ijsu.2006.06.015

4. Youlden DR, Cramb SM, Yip CH, Baade PD (2014) Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med 11:101–115. https://doi.org/10.7497/j.issn.2095-3941.2014.02.005

5. Sammons S, Kornblum NS, Blackwell KL (2019) Fulvestrant-based combination therapy for second-line treatment of hormone receptor-positive advanced breast cancer. Target Oncol 14:1–12. https://doi.org/10.1007/s11523-018-0587-9

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BOLERO-5: a phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER + /HER2- advanced breast cancer;Discover Oncology;2024-06-21

2. Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review;Breast Cancer Research;2024-05-22

3. Cardiotoxicity of Agents Used in Patients With Breast Cancer;JCO Oncology Practice;2024-01

4. Unfolding the role of the PI3K/AKT/MTOR pathway in male breast cancer: A pragmatic appraisal;The Breast;2023-12

5. Efficacy of everolimus‐based therapy in advanced triple‐positive breast cancer: Experience from three cancer centers in China;Thoracic Cancer;2023-11-07